In the latest interview with P&T, Dr. David Nash discusses the prospects for bipartisan legislation on reigning in prescription costs; eliminating drug shortages; and opaque hospital charges, along with the latest report from the Pharmacy Quality Alliance on access to care. He also discusses the need for value-based contracting, and his own personal plans vis-à-vis the Jefferson College of Population Health.
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
P&T May 2019
Table of Contents
Politics, Healthcare Costs, and Access: A Toxic Brew?